Corporate / M&A

IP / IT

Capital Markets

Employment and Executive Compensation

Bioversys

Homburger News

20250129_Bioversys

On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.
BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company&#8217;s most advanced R&amp;D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud &amp; Cie SA and Octavian AG as Selling Agents.
Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate / M&amp;A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP / IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Financing and Investment Products

Real Estate

Regulatory

YODA plc_web_640x140

Share-Image Teamplate Deals-and-Cases

On December 27, 2024, Yoda PLC, a Cyprus-based investment corporation listed on the Cyprus stock exchange (CSE: YODA), announced the completion of its major investment into ULTIMA CAPITAL SA (Ultima), a Swiss luxury real estate owner, developer and operator listed on BX Swiss (BX: ULTIMA).
As part of the transaction, Yoda has transferred to Ultima, by way of a contribution in kind, 100% of the issued share capital of its wholly-owned subsidiary Papacamp Investments Limited (Papacamp) at a contribution value of approximately CHF 484.6 m in return for 8,076,667 newly-issued shares of Ultima. Papacamp indirectly owns real estate properties and real estate developments in Greece within the luxury hospitality sector. As a result of the transaction, Yoda has become Ultima&#8217;s largest shareholder, with a shareholding interest in Ultima of approximately 53.8%. In addition, Yoda has granted Ultima a loan in the amount of CHF 71 m.
The Homburger team advising Yoda on all aspects of the transaction was led by Stefan Blunschi and included Micha Fankhauser, Oliver Kneubühl, Jonas Stähli and Leander Etter (all Corporate / M&amp;A), Lorenzo Togni and Kaiyan Yeo (both Capital Markets), Claudia Suter, Philippe Weber and Philippe Gobet (all Tax), Stefan Bindschedler and Nathalie Scherrer (both Financing and Investment Products), Stefan Gäumann and Olivier Bühlmann (both Real Estate), and Richard Stäuber and David Thomann (both Regulatory).

Homburger advised Yoda PLC on its investment into ULTIMA CAPITAL SA

Financial Market Regulation

On November 20, 2024, Sunshine SwissCo AG (a consortium led by EQT), the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers) announced the launch of an accelerated bookbuilding process to professional investors in Switzerland and to qualified investors outside Switzerland, which led to the successful placement of 16,000,000 shares in Galderma Group AG (Galderma) at a price of CHF 80 per share (the Placement), raising a total of ca. CHF 1.28 bn in total.
The Sellers will remain shareholders of 54.48% of the share capital of Galderma. EQT’s representation on the Board of Directors of Galderma remains unchanged as a result of the Placement. Such Placement will broaden Galderma&#8217;s shareholder base and free float. In connection therewith, the Sellers have agreed to a 90-day lock-up period, subject to certain customary exceptions, with respect to their remaining holding in Galderma.
The Placement is expected to be settled on November 25, 2024. Following the Placement, no changes to the Galderma board of directors and its governance are envisioned.
Homburger acted as transaction counsel to EQT.
The Homburger team was led by Frank Gerhard (Corporate / M&amp;A, Capital Markets) and included Lorenzo Togni, Estelle Piccard and Héloïse de Jamblinne (all Corporate / M&amp;A, Capital Markets), Micha Fankhauser (Financial Market Regulation) as well as Stefan Oesterhelt (Tax).

Homburger advises EQT on the sale of 6.73% of Galderma's share capital via an accelerated bookbuilding process

Lorenzo
Togni

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advised Yoda PLC on its investment into ULTIMA CAPITAL SA

Homburger advises EQT on the sale of 6.73% of Galderma's share capital via an accelerated bookbuilding process

Indicative Timeline for an IPO (Switzerland)

Indicative Timeline for an IPO (Switzerland)

Moving the Goalposts between Launch and Pricing oder Der Prospektnachtrag beim IPO unter bisherigem und zukünftigem Recht

Join the Team

Lorenzo Togni

Career

Languages

Bar Registration

Teams

LorenzoTogni

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advised Yoda PLC on its investment into ULTIMA CAPITAL SA

Homburger advises EQT on the sale of 6.73% of Galderma's share capital via an accelerated bookbuilding process

Indicative Timeline for an IPO (Switzerland)

Indicative Timeline for an IPO (Switzerland)

Moving the Goalposts between Launch and Pricing oder Der Prospektnachtrag beim IPO unter bisherigem und zukünftigem Recht

Join the Team

Lorenzo Togni

Career

Languages

Bar Registration

Teams

Lorenzo
Togni